TG Therapeutics, Inc. (0VGI.L)
USD 32.28
(-6.35%)
USD 32.28
(-6.35%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 169.08 Million USD | 25.26% |
| 2022 | 134.98 Million USD | -5.26% |
| 2021 | 142.47 Million USD | 34.04% |
| 2020 | 106.29 Million USD | -14.56% |
| 2019 | 124.39 Million USD | 108.79% |
| 2018 | 59.58 Million USD | -38.82% |
| 2017 | 97.38 Million USD | 77.76% |
| 2016 | 54.78 Million USD | -51.72% |
| 2015 | 113.47 Million USD | 30.81% |
| 2014 | 86.74 Million USD | 80.3% |
| 2013 | 48.11 Million USD | 637.5% |
| 2012 | 6.52 Million USD | 4.03% |
| 2011 | 6.27 Million USD | -73.87% |
| 2010 | 23.99 Million USD | 235.63% |
| 2009 | 7.15 Million USD | 27.12% |
| 2008 | 5.62 Million USD | 200.53% |
| 2007 | 1.87 Million USD | -3.69% |
| 2006 | 1.94 Million USD | 16.66% |
| 2005 | 1.66 Million USD | 39.32% |
| 2004 | 1.19 Million USD | 23.78% |
| 2003 | 966.02 Thousand USD | 67.21% |
| 2002 | 577.73 Thousand USD | 13.59% |
| 2001 | 508.61 Thousand USD | -75.55% |
| 2000 | 2.08 Million USD | 246.74% |
| 1999 | 600 Thousand USD | 0.0% |
| 1998 | 600 Thousand USD | 50.0% |
| 1997 | 400 Thousand USD | 33.33% |
| 1996 | 300 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 223.63 Million USD | 4.89% |
| 2024 Q1 | 213.21 Million USD | 26.1% |
| 2023 Q3 | 166.29 Million USD | -7.82% |
| 2023 Q2 | 180.4 Million USD | 6.17% |
| 2023 FY | 169.08 Million USD | 25.26% |
| 2023 Q4 | 169.08 Million USD | 1.68% |
| 2023 Q1 | 169.92 Million USD | 25.88% |
| 2022 FY | 134.98 Million USD | -5.26% |
| 2022 Q4 | 134.98 Million USD | 14.97% |
| 2022 Q1 | 132.64 Million USD | -6.9% |
| 2022 Q2 | 122.63 Million USD | -7.55% |
| 2022 Q3 | 117.41 Million USD | -4.26% |
| 2021 Q2 | 98.27 Million USD | -4.97% |
| 2021 Q3 | 98.17 Million USD | -0.1% |
| 2021 Q4 | 142.47 Million USD | 45.13% |
| 2021 FY | 142.47 Million USD | 34.04% |
| 2021 Q1 | 103.41 Million USD | -2.71% |
| 2020 Q3 | 103.19 Million USD | 2.79% |
| 2020 Q4 | 106.29 Million USD | 3.0% |
| 2020 FY | 106.29 Million USD | -14.56% |
| 2020 Q2 | 100.39 Million USD | -2.72% |
| 2020 Q1 | 103.2 Million USD | -17.04% |
| 2019 Q1 | 98.28 Million USD | 64.96% |
| 2019 Q4 | 124.39 Million USD | 4.43% |
| 2019 Q3 | 119.11 Million USD | 27.56% |
| 2019 Q2 | 93.38 Million USD | -4.99% |
| 2019 FY | 124.39 Million USD | 108.79% |
| 2018 Q1 | 35.76 Million USD | -63.28% |
| 2018 FY | 59.58 Million USD | -38.82% |
| 2018 Q4 | 59.58 Million USD | 39.76% |
| 2018 Q3 | 42.63 Million USD | -69.7% |
| 2018 Q2 | 140.71 Million USD | 293.48% |
| 2017 Q3 | 22.23 Million USD | -4.25% |
| 2017 Q2 | 23.22 Million USD | -81.16% |
| 2017 Q1 | 123.25 Million USD | 125.0% |
| 2017 Q4 | 97.38 Million USD | 337.95% |
| 2017 FY | 97.38 Million USD | 77.76% |
| 2016 Q4 | 54.78 Million USD | -27.62% |
| 2016 Q3 | 75.68 Million USD | 370.21% |
| 2016 Q2 | 16.09 Million USD | 51.61% |
| 2016 Q1 | 10.61 Million USD | -90.64% |
| 2016 FY | 54.78 Million USD | -51.72% |
| 2015 Q4 | 113.47 Million USD | 922.71% |
| 2015 FY | 113.47 Million USD | 30.81% |
| 2015 Q1 | 117.26 Million USD | 35.19% |
| 2015 Q2 | 10.65 Million USD | -90.91% |
| 2015 Q3 | 11.09 Million USD | 4.13% |
| 2014 Q2 | 56.3 Million USD | 1404.45% |
| 2014 Q1 | 3.74 Million USD | -92.22% |
| 2014 Q4 | 86.74 Million USD | 11.87% |
| 2014 FY | 86.74 Million USD | 80.3% |
| 2014 Q3 | 77.54 Million USD | 37.73% |
| 2013 Q3 | 9.66 Million USD | -45.9% |
| 2013 FY | 48.11 Million USD | 637.5% |
| 2013 Q4 | 48.11 Million USD | 397.98% |
| 2013 Q2 | 17.85 Million USD | 167.04% |
| 2013 Q1 | 6.68 Million USD | 2.51% |
| 2012 FY | 6.52 Million USD | 4.03% |
| 2012 Q1 | 5.88 Million USD | -6.13% |
| 2012 Q3 | 7.33 Million USD | 8.8% |
| 2012 Q2 | 6.74 Million USD | 14.56% |
| 2012 Q4 | 6.52 Million USD | -11.1% |
| 2011 Q3 | 18.35 Million USD | -10.49% |
| 2011 Q4 | 6.27 Million USD | -65.84% |
| 2011 Q1 | 19.95 Million USD | -16.85% |
| 2011 Q2 | 20.51 Million USD | 2.77% |
| 2011 FY | 6.27 Million USD | -73.87% |
| 2010 Q1 | 27.59 Million USD | 285.97% |
| 2010 FY | 23.99 Million USD | 235.63% |
| 2010 Q4 | 23.99 Million USD | -3.11% |
| 2010 Q3 | 24.77 Million USD | -2.39% |
| 2010 Q2 | 25.37 Million USD | -8.06% |
| 2009 Q3 | 7.32 Million USD | -1.6% |
| 2009 Q1 | 6.56 Million USD | 16.71% |
| 2009 Q4 | 7.15 Million USD | -2.41% |
| 2009 Q2 | 7.44 Million USD | 13.43% |
| 2009 FY | 7.15 Million USD | 27.12% |
| 2008 Q3 | 4.96 Million USD | 12.27% |
| 2008 FY | 5.62 Million USD | 200.53% |
| 2008 Q1 | 1.78 Million USD | -4.55% |
| 2008 Q2 | 4.42 Million USD | 147.44% |
| 2008 Q4 | 5.62 Million USD | 13.34% |
| 2007 Q1 | 2.19 Million USD | 12.84% |
| 2007 FY | 1.87 Million USD | -3.69% |
| 2007 Q3 | 1.79 Million USD | -29.21% |
| 2007 Q4 | 1.87 Million USD | 4.5% |
| 2007 Q2 | 2.53 Million USD | 15.38% |
| 2006 Q4 | 1.94 Million USD | 37.41% |
| 2006 FY | 1.94 Million USD | 16.66% |
| 2006 Q3 | 1.41 Million USD | -36.15% |
| 2006 Q2 | 2.21 Million USD | -1.43% |
| 2006 Q1 | 2.24 Million USD | 34.89% |
| 2005 Q3 | 1.8 Million USD | 1.87% |
| 2005 FY | 1.66 Million USD | 39.32% |
| 2005 Q1 | 1.27 Million USD | 6.26% |
| 2005 Q2 | 1.77 Million USD | 39.73% |
| 2005 Q4 | 1.66 Million USD | -7.9% |
| 2004 Q3 | 1.47 Million USD | 136.2% |
| 2004 Q4 | 1.19 Million USD | -18.93% |
| 2004 Q2 | 624.41 Thousand USD | -17.6% |
| 2004 Q1 | 757.78 Thousand USD | -21.56% |
| 2004 FY | 1.19 Million USD | 23.78% |
| 2003 Q3 | 1.26 Million USD | 20.03% |
| 2003 Q2 | 1.05 Million USD | -0.84% |
| 2003 Q1 | 1.06 Million USD | 84.04% |
| 2003 FY | 966.02 Thousand USD | 67.21% |
| 2003 Q4 | 966.02 Thousand USD | -23.67% |
| 2002 Q2 | 427.73 Thousand USD | -11.75% |
| 2002 Q3 | 503.94 Thousand USD | 17.82% |
| 2002 FY | 577.73 Thousand USD | 13.59% |
| 2002 Q4 | 577.73 Thousand USD | 14.64% |
| 2002 Q1 | 484.7 Thousand USD | -4.7% |
| 2001 Q4 | 508.61 Thousand USD | -32.04% |
| 2001 Q1 | 779.24 Thousand USD | -62.54% |
| 2001 Q2 | 706.87 Thousand USD | -9.29% |
| 2001 Q3 | 748.35 Thousand USD | 5.87% |
| 2001 FY | 508.61 Thousand USD | -75.55% |
| 2000 Q3 | 1.06 Million USD | 95.73% |
| 2000 Q1 | 495.94 Thousand USD | -17.34% |
| 2000 Q2 | 542.48 Thousand USD | 9.38% |
| 2000 Q4 | 2.08 Million USD | 95.94% |
| 2000 FY | 2.08 Million USD | 246.74% |
| 1999 Q2 | 400 Thousand USD | 33.33% |
| 1999 Q3 | 200 Thousand USD | -50.0% |
| 1999 Q4 | 600 Thousand USD | 200.0% |
| 1999 FY | 600 Thousand USD | 0.0% |
| 1999 Q1 | 300 Thousand USD | -50.0% |
| 1998 Q3 | 600 Thousand USD | 0.0% |
| 1998 FY | 600 Thousand USD | 50.0% |
| 1998 Q4 | 600 Thousand USD | 0.0% |
| 1998 Q1 | 200 Thousand USD | -50.0% |
| 1998 Q2 | 600 Thousand USD | 200.0% |
| 1997 Q4 | 400 Thousand USD | 33.33% |
| 1997 Q1 | 300 Thousand USD | 0.0% |
| 1997 FY | 400 Thousand USD | 33.33% |
| 1997 Q2 | 300 Thousand USD | 0.0% |
| 1997 Q3 | 300 Thousand USD | 0.0% |
| 1996 Q3 | 400 Thousand USD | 0.0% |
| 1996 Q4 | 300 Thousand USD | -25.0% |
| 1996 FY | 300 Thousand USD | 0.0% |
| 1996 Q2 | 400 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Editas Medicine, Inc. | 150.05 Million USD | -12.681% |
| Dynavax Technologies Corporation | 375.02 Million USD | 54.914% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 65.313% |
| Perrigo Company plc | 6.04 Billion USD | 97.201% |
| Illumina, Inc. | 4.36 Billion USD | 96.127% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 99.674% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | 13.617% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 99.754% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 99.178% |
| Heron Therapeutics, Inc. | 256.47 Million USD | 34.075% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 97.621% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -353.408% |
| Waters Corporation | 3.47 Billion USD | 95.136% |
| Biogen Inc. | 12.04 Billion USD | 98.596% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -105.118% |
| Evolus, Inc. | 209.68 Million USD | 19.363% |
| Adicet Bio, Inc. | 37.12 Million USD | -355.509% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -145.91% |
| bluebird bio, Inc. | 424.62 Million USD | 60.18% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 74.412% |
| FibroGen, Inc. | 585.72 Million USD | 71.133% |
| Agilent Technologies, Inc. | 4.91 Billion USD | 96.562% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -380.668% |
| Homology Medicines, Inc. | 118.53 Million USD | -42.648% |
| Geron Corporation | 146.12 Million USD | -15.711% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 95.826% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 72.627% |
| Myriad Genetics, Inc. | 312.9 Million USD | 45.962% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -742.434% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | 32.584% |
| Zoetis Inc. | 9.29 Billion USD | 98.181% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -243.836% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | 95.177% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 91.054% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 96.717% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -249.025% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 93.505% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | 36.13% |
| Verastem, Inc. | 71.18 Million USD | -137.529% |
| Nektar Therapeutics | 267.04 Million USD | 36.683% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | 57.437% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -320.338% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 92.97% |
| OPKO Health, Inc. | 622.47 Million USD | 72.837% |
| Exelixis, Inc. | 678.44 Million USD | 75.078% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 83.413% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -47.271% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -1249.011% |
| uniQure N.V. | 624.01 Million USD | 72.904% |
| Imunon, Inc. | 8.53 Million USD | -1882.14% |
| Blueprint Medicines Corporation | 918.64 Million USD | 81.594% |
| Insmed Incorporated | 1.66 Billion USD | 89.825% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 89.749% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -34.089% |
| Incyte Corporation | 1.59 Billion USD | 89.381% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | 85.738% |